These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32355826)

  • 21. Efficacy and safety of single-dose dexamethasone implantation for patients with persistent diabetic macular edema: a systematic review and meta-analysis.
    Yuan Q; Liu Y; Xu H; Gao Y; Qin L; Gou Y; Tao M; Zhang M
    Graefes Arch Clin Exp Ophthalmol; 2022 Feb; 260(2):405-413. PubMed ID: 34550419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Anti-VEGF therapy for diabetic macular edema. From theory to clinical practice].
    Fursova AZ; Chubar NV; Tarasov MS; Niculich IF; Vasilyeva MA; Gusarevich OG
    Vestn Oftalmol; 2018; 134(2):12-22. PubMed ID: 29771880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial.
    Jampol LM; Glassman AR; Bressler NM; Wells JA; Ayala AR;
    JAMA Ophthalmol; 2016 Dec; 134(12):. PubMed ID: 27711918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.
    Chen YY; Chang PY; Wang JK
    Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Switching to Conbercept in Diabetic Macular Edema After Unsatisfactory Response to Previous Intravitreal Injection of Ranibizumab.
    Xing P; Meng B; Hu X; Qu W; Wang S
    Clin Ophthalmol; 2023; 17():3491-3497. PubMed ID: 38026602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dril Influences Short-term Visual Outcome after Intravitreal Corticosteroid Injection for Refractory Diabetic Macular Edema.
    Luís ME; Sampaio F; Costa J; Cabral D; Teixeira C; Ferreira JT
    Curr Eye Res; 2021 Sep; 46(9):1378-1386. PubMed ID: 33463388
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparison of efficacy of conbercept, aflibercept, and ranibizumab ophthalmic injection in the treatment of macular edema caused by retinal vein occlusion: a Meta-analysis.
    Xing Q; Dai YN; Huang XB; Peng L
    Int J Ophthalmol; 2023; 16(7):1145-1154. PubMed ID: 37465496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current Outcomes of Anti-VEGF Therapy in the Treatment of Macular Oedema Secondary to Branch Retinal Vein Occlusions: A Meta-Analysis.
    Spooner K; Hong T; Fraser-Bell S; Chang AA
    Ophthalmologica; 2019; 242(3):163-177. PubMed ID: 31158837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis.
    Spooner K; Hong T; Wijeyakumar W; Chang AA
    Clin Ophthalmol; 2017; 11():161-177. PubMed ID: 28123287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis.
    Pessoa B; Malheiro L; Carneiro I; Monteiro S; Coelho J; Coelho C; Figueira J; Meireles A; Melo Beirão JN
    Clin Ophthalmol; 2021; 15():253-260. PubMed ID: 33519187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema.
    Fouda SM; Bahgat AM
    Clin Ophthalmol; 2017; 11():567-571. PubMed ID: 28356711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD.
    Waizel M; Todorova MG; Masyk M; Wolf K; Rickmann A; Helaiwa K; Blanke BR; Szurman P
    BMC Ophthalmol; 2017 May; 17(1):79. PubMed ID: 28535756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema.
    Alsaedi NG; Alselaimy RM; Alshamrani AA; AlAjmi M; Khandekar R; Al-Dhibi H; Al-Abdullah AA
    Clin Ophthalmol; 2021; 15():2975-2980. PubMed ID: 34285463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship Between Macular Thickness and Visual Acuity in the Treatment of Diabetic Macular Edema With Anti-VEGF Therapy: Systematic Review.
    Wang P; Hu Z; Hou M; Norman PA; Chin EK; Almeida DR
    J Vitreoretin Dis; 2023; 7(1):57-64. PubMed ID: 37008395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases With Non-Response to Bevacizumab.
    Ashraf M; Souka AA; ElKayal H
    Ophthalmic Surg Lasers Imaging Retina; 2017 Mar; 48(3):230-236. PubMed ID: 28297035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Ranibizumab and aflibercept for diabetic macular edema-retrospective study with real-life data after 12 months].
    Holbach B; Zeman F; Helbig H; Gamulescu MA
    Ophthalmologe; 2020 Jul; 117(7):687-692. PubMed ID: 31705192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of conbercept and ranibizumab for the treatment efficacy of diabetic macular edema: a Meta-analysis and systematic review.
    Liu WS; Li YJ
    Int J Ophthalmol; 2019; 12(9):1479-1486. PubMed ID: 31544046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Shalchi Z; Mahroo O; Bunce C; Mitry D
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD009510. PubMed ID: 32633861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different Anti-Vascular Endothelial Growth Factor for Patients With Diabetic Macular Edema: A Network Meta-Analysis.
    Wang X; He X; Qi F; Liu J; Wu J
    Front Pharmacol; 2022; 13():876386. PubMed ID: 35814207
    [No Abstract]   [Full Text] [Related]  

  • 40. One-year results of switching to aflibercept for persistent diabetic macular edema resistant to bevacizumab.
    Abouhussein MA; Gomaa AR
    Taiwan J Ophthalmol; 2021; 11(3):266-272. PubMed ID: 34703742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.